Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Chi-Feng YenChao-Kai HsuHsing-San YangChaw-Ning LeeChing-Chi ChiWen-Hung ChungChih-Liang WangJong-Hwei Su PangChuang-Wei WangYu-Shien KoChun-Wei LuPublished in: International journal of dermatology (2019)
Betaxolol 0.25% ophthalmic solution is an effective, safe, and pain-relieving treatment for patients suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions and deep fissures.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- small cell lung cancer
- high glucose
- advanced non small cell lung cancer
- ejection fraction
- drug induced
- newly diagnosed
- chronic kidney disease
- chronic pain
- prognostic factors
- peritoneal dialysis
- pain management
- early onset
- oxidative stress
- spinal cord
- endothelial cells
- stress induced